Pathophysiology of CKD-MBD

被引：0
|
作者：
Elder, Grahame J. [1 ,2 ]
机构：
[1] Westmead Hosp, Dept Renal Med, Westmead, NSW 2145, Australia
[2] Garvan Inst Med Res, Osteoporosis & Bone Biol Program, Sydney, NSW, Australia
来源：
CLINICAL REVIEWS IN BONE AND MINERAL METABOLISM | 2012年 / 10卷 / 03期
关键词：
CKD-MBD; Bone; Osteocyte; Osteoblast; Osteoclast; Fibroblast growth factor 23; Klotho; Parathyroid hormone; Renal adaptation; Pathophysiology;
D O I：
10.1007/s12018-011-9120-8
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
To maintain calcium and phosphate balance despite declining kidney function, adaptations must begin in the earliest stages of chronic kidney disease (CKD). These are generally successful in maintaining calcium and phosphate levels within the normal range through CKD stages 1-4. Although routine biochemistry is not informative about net gain of these minerals, newer markers such as Klotho and fibroblast growth factor 23 may provide clues to these early adjustments and be of prognostic value. Bone cells play a central role in modulating responses to CKD. This review describes that role and highlights the dynamic communication between bone and the kidneys.
引用
收藏
页码：128 / 141
页数：14
相关论文
共 50 条
  • [1] Pathophysiology of CKD-MBD
    Grahame J. Elder
    Clinical Reviews in Bone and Mineral Metabolism, 2012, 10 (3): : 128 - 141
  • [2] microRNAs in the pathophysiology of CKD-MBD: Biomarkers and innovative drugs
    Meuth, Valerie Metzinger-Le
    Burtey, Stephane
    Maitrias, Pierre
    Massy, Ziad A.
    Metzinger, Laurent
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2017, 1863 (01): : 337 - 345
  • [3] Sclerostin and CKD-MBD
    Susan C. Schiavi
    Current Osteoporosis Reports, 2015, 13 : 159 - 165
  • [4] Sclerostin and CKD-MBD
    Schiavi, Susan C.
    CURRENT OSTEOPOROSIS REPORTS, 2015, 13 (03) : 159 - 165
  • [5] Hope for CKD-MBD Patients: New Diagnostic Approaches for Better Treatment of CKD-MBD
    Hocher, Berthold
    Pasch, Andreas
    KIDNEY DISEASES, 2017, 3 (01) : 8 - 14
  • [6] The Role of Bone Biopsy in the Management of CKD-MBD: CKD-Related Osteoporosis or CKD-MBD/Osteoporosis?
    Ferreira, Ana Carina
    Cohen-Solal, Martine
    D'Haese, Patrick C.
    Ferreira, Anibal
    CALCIFIED TISSUE INTERNATIONAL, 2021, 109 (01) : 112 - 112
  • [7] CKD-MBD as a systemic disorder
    Fukagawa, Masafumi
    Drueeke, Tilman B.
    BONE, 2009, 45 : S1 - S1
  • [8] Calciphylaxis: Beyond CKD-MBD
    Fernandez, Maria
    Morales, Enrique
    Gutierrez, Eduardo
    Polanco, Natalia
    Hernandez, Eduardo
    Merida, Eva
    Praga, Manuel
    NEFROLOGIA, 2017, 37 (05): : 501 - 507
  • [9] A Japanese approach for CKD-MBD
    Yokoyama, Keitaro
    Taniguchi, Masatomo
    Fukagawa, Masafumi
    KIDNEY INTERNATIONAL SUPPLEMENTS, 2013, 3 (05) : 451 - 456
  • [10] The Role of Bone Biopsy in the Management of CKD-MBD: CKD-Related Osteoporosis or CKD-MBD/Osteoporosis?
    Ana Carina Ferreira
    Martine Cohen-Solal
    Patrick C. D’Haese
    Aníbal Ferreira
    Calcified Tissue International, 2021, 109 : 112 - 112
12345